ARTIMPLANT INTERIM REPORT JANUARY - SEPTEMBER 2007

ARTIMPLANT INTERIM REPORT JANUARY - SEPTEMBER 2007

Västra Frölunda, Sweden, November 9, 2007

• Net revenue for the third quarter increased to SEK 2.6 million (0.9) and for
the first nine months to SEK 11.2 million (3.9)*
• The net loss for the third quarter amounted to SEK 3.6 million (15.9) and for
the first nine months to SEK 11.3 million (46.5)
• The net loss for the third quarter, excluding a non-recurring item, amounted
to SEK 3.6 million (10.4) and for the first nine months to SEK 9.7 million
(29.4)
• Earnings per share, including a non-recurring item, amounted to SEK -0.19
(-0.79)
• Artelon® Tissue Reinforcement was granted clearance in the USA to be marketed
for all tendons of the rotator cuff and for four new indications
• Kauko Haapasaari has been employed as head of marketing
• More than 5,000 patients have been treated with Artelon® implants since the
launch

EVENTS AFTER THE PERIOD-END
• Biomet's agreement for the rotator cuff application was renegotiated to
non-exclusive status                                  
• Biomet has been granted a global, non-exclusive right to   market SportMesh™
for four new indications 
• Artimplant's obligation to pay future royalties to the inventor of Artelon®
was cleared for SEK 2.8 million	



This information is information which Artimplant shall make public pursuant to
the Swedish Financial Instruments Act and the Swedish Securities Exchange and
Clearing Operations Act and/or stock market agreements. Information was made
available for publication on November 9, 2007 at 8:45 am.

Artimplant will hold a telephone conference on this report on November 9, 2007
at 11 am. For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year


For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Web site: www.artimplant.com

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.


Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.